Backstory
Mestastop is founded by Dr. Arnab Roy Chowdhury and his partner-in-life Dr. Debabani Roy Chowdhury.
Arnab is trained in Biochemistry, Molecular, and Cellular Biology, with more than 20 years of experience fighting diseases. During his Ph.D. and post-doctoral studies, he focused on neglected parasitic diseases like Kala-azar and Sleeping Sickness. Debabani is trained in Immunology and Cell Biology, also having more than 15 years of experience.
Returning from Johns Hopkins School of Medicine to India in 2009, Arnab got involved in drug discovery, taking a keen interest in disease pathophysiology, especially in inflammation and oncology. Over the next decade, he has lead several drug discovery programs in collaboration with Big Pharma and smaller biotechs, e.g. GSK, Abbvie, Takeda, Onconova delivering leads, first-in-class, and pre-IND candidates. Debabani, 
working on malaria vaccine at Bloomberg School of Public Health, joined CCMB, Hyderabad, and later won a DST-WoSA grant, working on human X chromosome inactivation.
Arnab moved onto Amgen India in Jan 2017 to pursue his oncology drug discovery ambitions and finally started his start-up in 2018. He is passionate about science, does not believe in mediocrity or cutting corners, and breathes integrity in all his actions. Debabani then joined hands with him to head the R&D and operations, once wet lab started.
“Mestastop is charting a pioneering and much-needed path to early detection of metastasis. Such work is key to furthering mankind’s understanding of human health”
“If Mestastop can predict metastasis probability of primary cancer patients, that will be a game changer for doctors”
“Mestastop provides a great opportunity at finding solutions to the unmet medical needs in cancer care”
“Concept-wise, it is a much-needed approach to address metastasis; looks very interesting and perhaps doable with Arnab’s keen interest and passion”
“Mestastop platform will play an instrumental role in changing cancer treatment in India and the world around”
